Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 6/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.38 |
| ▸ | ERBB3 | P21860 | 3/20 | 0.38 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PGK1 | P00558 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | UBE2N | P61088 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | BCL6 | P41182 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9972402 | 0.84 | EGFR (0.42) | CSF1RSYKEGFRERBB2ERBB3 | |
| SCHEMBL22135123 | 0.81 | SYK (0.35) | CSF1RSYKEGFRERBB2ERBB3 | |
| SCHEMBL9965325 | 0.81 | CSF1R (0.42) | CSF1RSYKEGFRERBB2ERBB3 | |
| SCHEMBL22138738 | 0.80 | SYK (0.34) | CSF1RSYKEGFRERBB2ERBB3 | |
| SCHEMBL9939641 | 0.80 | BRD4 (0.38) | CSF1RSYKP2RX3 | |
| SCHEMBL23624476 | 0.75 | TNF (0.48) | CSF1RSYKEGFRERBB2ERBB3 | |
| SCHEMBL25895044 | 0.72 | SYK (0.41) | CSF1RSYKEGFRERBB2ERBB3 | |
| SCHEMBL9939040 | 0.71 | SYK (0.40) | SYKEGFRERBB2ERBB3ERBB4 | |
| SCHEMBL15301493 | 0.71 | GALR2 (0.40) | — | |
| SCHEMBL9938726 | 0.71 | SYK (0.40) | SYKGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651416-B1 | COMPOUNDS USEFUL FOR TREATING AIDS | ABIVAX (FR) | 2018-05-09 | — | — | EP | claimed |
| US-9061999-B2 | Compounds useful for treating AIDS | ABIVAX (FR) | 2015-06-23 | — | — | US | claimed |
| US-20130267703-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SPLICOS (FR) | 2013-10-10 | — | — | US | claimed |
| WO-2023139233-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A JAK INHIBITOR | ABIVAX (FR) | 2023-07-27 | — | — | WO | disclosed |
| EP-4215196-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A JAK INHIBITOR | ABIVAX (FR) | 2023-07-26 | — | — | EP | disclosed |
| WO-2023135207-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A S1P RECEPTOR MODULATOR | ABIVAX (FR) | 2023-07-20 | — | — | WO | disclosed |
| EP-4212156-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A S1P RECEPTOR MODULATOR | ABIVAX (FR) | 2023-07-19 | — | — | EP | disclosed |
| US-11649211-B2 | Use of quinoline derivatives for the treatment of inflammatory diseases | ABIVAX (FR) | 2023-05-16 | — | — | US | disclosed |
| US-11649210-B2 | Use of quinoline derivatives for the treatment of inflammatory diseases | ABIVAX (FR) | 2023-05-16 | — | — | US | disclosed |
| US-11649211-B2 | Use of quinoline derivatives for the treatment of inflammatory diseases | ABIVAX (FR) | 2023-05-16 | — | — | US | disclosed |
| US-11649210-B2 | Use of quinoline derivatives for the treatment of inflammatory diseases | ABIVAX (FR) | 2023-05-16 | — | — | US | disclosed |
| US-9061999-B2 | Compounds useful for treating AIDS | ABIVAX (FR) | 2015-06-23 | — | — | US | disclosed |
| US-9061999-B2 | Compounds useful for treating AIDS | ABIVAX (FR) | 2015-06-23 | — | — | US | disclosed |
| EP-2651416-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | Splicos (FR) | 2013-10-23 | — | — | EP | disclosed |
| US-20130267703-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SPLICOS (FR) | 2013-10-10 | — | — | US | disclosed |
| US-20130267703-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SPLICOS (FR) | 2013-10-10 | — | — | US | disclosed |
| US-20130267703-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SPLICOS (FR) | 2013-10-10 | — | — | US | disclosed |
| WO-2012080953-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SPLICOS (FR) | 2012-06-21 | — | — | WO | disclosed |
| EP-2465502-A1 | Compounds useful for treating AIDS | Société Splicos (FR) | 2012-06-20 | — | — | EP | disclosed |
| EP-2465502-A1 | Compounds useful for treating AIDS | Société Splicos (FR) | 2012-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267703-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | CBR3, CBR1, CCR10 | CSF1R 1735/4885SYK 1956/4885EGFR 2519/4885 |
| US-11649210-B2 | Use of quinoline derivatives for the treatment of inflammatory diseases | NR1H4, NR1I3, NR1H3 | CSF1R 1539/4885SYK 2468/4885EGFR 4721/4885 |
| US-11649211-B2 | Use of quinoline derivatives for the treatment of inflammatory diseases | NR1H4, NR1I3, NR1H3 | CSF1R 1539/4885SYK 2468/4885EGFR 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.